iRep
Introduction
Chapter
-
1
Introduction
-
2
Benefits of personalised medicine
-
3
Evolution of RAS testing
-
4
PRIME: a pivotal study in mCRC
-
5
PEAK: Vectibix® vs bevacizumab (phase 2 study)
-
6
Options after 1st line Vectibix® + FOLFOX
-
7
Summary
Sorry we are unable to help you in this occasion. Please contact us
-
Why should 1st line treatment with Vectibix® in combination with FOLFOX be considered in wild-type RAS metastatic colorectal cancer patients?
-
If I use Vectibix® + FOLFOX in 1st line, what are the guidelines recommending in 2nd line?
-
Should I test all of my patients for RAS tumour status?
-
What resectability data are available for Vectibix®?
-
How do I manage skin toxicity with Vectibix®?
-
Why didn’t Vectibix® achieve a significant overall survival benefit in the original PRIME analysis?
-
Is FOLFOX an adequate comparator now?
-
PEAK is a phase 2 trial – why is it important?
-
What is the difference between Vectibix® and cetuximab?
-
Why are retrospective data important?